


# PHARMACEUTICAL ECONOMICS



## PRACTICE CONTACTS

George Korenko

Tram Nguyen

## RELATED CAPABILITIES

Antitrust & Competition

Antitrust Litigation

Edgeworth's experts have deep experience analyzing economic issues in the pharmaceutical industry in the areas of antitrust, intellectual property, commercial damages, and consumer protection. Since our founding in 2009, Edgeworth's economists have served as both testifying and consulting economists on a wide array of industry-specific matters before courts and regulatory authorities.

Our pharmaceutical economics experts have assisted clients across the industry, including brand and generic pharmaceutical companies, biotechnology companies, product manufacturers, healthcare providers, and insurers. We have performed analysis and testified in a variety of cases on issues including class certification, antitrust liability, antitrust damages, patent infringement, and product liability. In these contexts, Edgeworth experts have assessed economic and econometric issues in the pharmaceutical industry relating to:

- Pay for Delay
- Product Hopping
- Price Fixing
- Bid Rigging
- Exclusive Contracting
- Consumer Protection
- False Advertising
- Intellectual Property Damages
- Valuation
- Contract Disputes

## CASE HIGHLIGHTS

Edgeworth Client Prevails in Rare Antitrust Trial  
Business & Regulatory Consulting, 07.2022

Edgeworth Client Receives Settlement Resolving Patent and Antitrust Litigation  
Litigation, 07.24.2019

## PUBLICATIONS

Finding Uninjured Consumers In Drug Antitrust Class Actions  
Published Article, *Law360*, 05.16.2022

Lamictal and the Myth of “Generic” “Pay-for-Delay” Cases  
Published Article, *Law360*, 07.21.2020

## EDGEWORTH INSIGHTS

Troubles with Identifying Uninjured Class Members in Pay-for-delay Pharmaceutical Cases  
Blog, 09.06.2022

## THE ANTITRUST PRESCRIPTION

FTC Again Takes Strong Stance Against Improper Listing of Patents in the Orange Book  
Economic Implications on Brand-Generic Settlement and Future Pharmaceutical Antitrust Litigation  
Blog, 11.29.2023

FTC Challenges Amgen Acquisition of Horizon: More to Come Under Broadened Section 5  
Blog, 07.26.2023

Merck and Glenmark Settle on the Eve of a Rare Pay-For-Delay Trial  
Blog, 05.30.2023

Don't Count Out Numerosity  
Blog, 03.15.2023

## SPEAKING ENGAGEMENTS

Navigating Antitrust Issues in the Pharmaceutical and Life Science Industries: Key Trends and Challenges Explored  
Event, 06.21.2022

Conflicting Decisions in Pharmaceutical Class Certification  
Event, Antitrust Economics Workshop | Fordham Competition Law Institute, 10.07.2020

Emerging Antitrust Issues—Implications to the Life Sciences Industry  
Event, 01.10.2019

## NEWS

Edgeworth Economics' Pharmaceutical Economics Practice Launches *The Antitrust Prescription* Blog  
Press Release, 03.15.2023

## PROJECT EXPERIENCE

Edgeworth has worked on numerous matters involving the economics of the pharmaceutical industry and drug pricing for both direct and indirect purchasers, including matters involving allegations of delayed generic entry, reverse payments, product-hopping, or other exclusionary practices. Representative matters include:

- In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
- In Re: Opana ER Antitrust Litigation
- In Re: Solodyn (Minocycline Hydrochloride) Antitrust Litigation
- In Re: Nexium (Esomeprazole) Antitrust Litigation
- In Re: Wellbutrin XL Antitrust Litigation